9 unchanged sentences
Common Stock Performance
−Removed: The graph below shows the cumulative total return assuming an investment of $100 on December 31, 2014 , in each of the Company’s common stock, the Standard & Poor’s, or S&P Composite-500 Stock Index and the S&P 500 healthcare Index, or Peer Group, and assuming that all dividends were reinvested.
−Removed: Comparison of Five Year Cumulative Total Return
+Added: The graph below shows the cumulative total return assuming an investment of $100 on December 31, 2015, in each of the Company’s common stock, the Standard & Poor’s, or S&P Composite-500 Stock Index and the S&P 500 Health Care Index, or Peer Group, and assuming that all dividends were reinvested.
+Added: Comparison of Cumulative Total Return
+Added: 12/2015 12/2016 12/2017 12/2018 12/2019 12/2020
Laboratory Corporation of America Holdings $ 100.00 $ 103.83 $ 129.01 $ 102.20 $ 136.82 $ 164.63
3 unchanged sentences
The following table sets forth information with respect to purchases of shares of the Company’s Common Stock made during the quarter ended December 31, 2020, by or on behalf of the Company:
−Removed: Total Number of Shares Repurchased
−Removed: Average Price Paid Per Share
−Removed: Total Number of Shares Repurchased as Part of Publicly Announced Program
−Removed: Maximum Dollar Value of Shares that May Yet Be Repurchased Under the Program
+Added: Total Number of Shares Repurchased Average Price Paid Per Share Total Number of Shares Repurchased as Part of Publicly Announced Program Maximum Dollar Value of Shares that May Yet Be Repurchased Under the Program
October 1 - October 31 — $ — — $ 800.0
1 unchanged sentence
December 1 - December 31 — — — 800.0
−Removed: At the end of 2018 , the Company had outstanding authorization from the board of directors to purchase up to $443.5 of Company common stock.
−Removed: On February 6, 2019 , the board of directors replaced the Company’s existing share repurchase plan with a new plan authorizing repurchase of up to $1.25 billion of the Company’s shares.
+Added: At the end of 2019, the Company had outstanding authorization from the board of directors to purchase $900.0 of Company common stock.
+Added: During three months ended March 31, 2020, the Company purchased 0.6 shares of its common stock at an average price of $178.85 for a total cost of $100.0.
+Added: When the Company repurchases shares, the amount paid to repurchase the shares in excess of the par or stated value is allocated to additional paid-in-capital unless subject to limitation or the balance in additional paid-in-capital is exhausted.
+Added: Remaining amounts are recognized as a reduction in retained earnings.
+Added: The Company reinstated its share repurchase program in October 2020 following the temporary suspension of stock repurchases beginning in March 2020 as a result of the anticipated impact of the COVID-19 pandemic.
+Added: At the end of 2020, the Company had outstanding authorization from the board of directors to purchase up to $800.0 of the Company's common stock.
The repurchase authorization has no expiration date.
−Removed: During 2019 , the Company purchased 2.9 shares of its common stock at an average price of $154.94 for a total cost of $450.0 , of which $100.0 was repurchased prior to the new plan in February 2019.
−Removed: At the end of 2019 , the Company had outstanding authorization from the board of directors to purchase an additional $900.0 of Company common stock.
SELECTED FINANCIAL DATA (in millions, except per share amounts)
−Removed: The selected financial data presented below under the captions “Statement of Operations Data” and “Balance Sheet Data” as of and for the five-year period ended December 31, 2019 , are derived from consolidated financial statements of the Company, which have been audited by an independent registered public accounting firm.
−Removed: Years Ended December 31,
−Removed: Statement of Operations Data :
−Removed: Operating income (h)
−Removed: Net earnings attributable to Laboratory
−Removed: Corporation of America Holdings
−Removed: Basic earnings per common share
−Removed: Diluted earnings per common share
−Removed: Basic weighted average common shares outstanding
−Removed: Diluted weighted average common shares outstanding
−Removed: Balance Sheet Data:
−Removed: Cash and cash equivalents and short-term investments
−Removed: Goodwill and intangible assets, net (g)
−Removed: Total assets (g) (f)
−Removed: Long-term obligations (f)
−Removed: Total shareholders' equity
−Removed: During 2019 , the Company recorded net restructuring charges of $54.6 .
−Removed: The charges were comprised of $32.9 in severance and other personnel costs and $24.9 in facility-related costs primarily associated with facility closures and general integration initiatives.
−Removed: These charges were offset by the reversal of previously established reserves of $1.7 in unused severance and $1.5 in unused facility-related costs.
−Removed: During 2018 , the Company recorded net restructuring charges of $48.1 .
−Removed: The charges were comprised of $40.3 in severance and other personnel costs and $11.8 in facility-related costs primarily associated with facility closures and general integration initiatives.
−Removed: These charges were offset by the reversal of previously established reserves of $2.0 in unused severance and $2.0 in unused facility-related costs.
−Removed: During 2017, the Company recorded net restructuring charges of $70.9.
−Removed: The charges were comprised of $36.1 in severance and other personnel costs and $39.9 in facility-related costs primarily associated with facility closures and general integration initiatives.
−Removed: These charges were offset by the reversal of previously established reserves of $0.5 in unused severance and $4.6 in unused facility-related costs.
−Removed: The Company also recognized asset impairment losses of $23.5 related to the termination of software development projects within the Covance Drug Development (CDD) segment and the forgiveness of certain indebtedness for LabCorp Diagnostics (LCD) customers in areas heavily impacted by hurricanes during the third quarter.
−Removed: During 2016, the Company recorded net restructuring charges of $58.4.
−Removed: The charges were comprised of $30.9 in severance and other personnel costs and $33.8 in facility-related costs primarily associated with facility closures and general integration initiatives.
−Removed: These charges were offset by the reversal of previously established reserves of $2.8 in unused severance and $3.5 in unused facility-related costs.
−Removed: During 2015, the Company recorded net restructuring charges of $113.9.
−Removed: The charges were comprised of $59.2 in severance and other personnel costs and $55.8 in facility-related costs primarily associated with facility closures and general integration initiatives.
−Removed: These charges were offset by the reversal of previously established reserves of $1.1 in unused facility-related costs.
−Removed: See Note 5 Leases and Note 12 Debt to the Consolidated Financial Statements.
−Removed: During 2016, the Company revised the final purchase price allocation for Covance.
−Removed: As a result, an out of period adjustment of $25.6 was recorded to reduce goodwill and increase a deferred tax asset as of December 31, 2015.
−Removed: The Company concluded that the impact of this adjustment was not material to the current or prior periods.
−Removed: Net earnings attributable to Laboratory Corporation of America Holdings in 2017 includes a provisional net benefit of $519.0 due to the Tax Cuts and Jobs Act (TCJA).
−Removed: For additional information on the TCJA, see Note 14 Income Taxes to the Consolidated Financial Statements.
+Added: Not applicable.
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.